The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

LI.s

Heart failure (biventricular, congestive)

Publications

Fukuo A, Imamura T, Onoda H, Kinugawa K

Successful Management of Osimertinib-Induced Heart Failure.

Medicina (Kaunas, Lithuania) 2022 Feb 18;58; — 2022 Feb 18

Ikebe S, Amiya R, Minami S, Ihara S, Higuchi Y, Komuta K

Osimertinib-induced cardiac failure with QT prolongation and torsade de pointes in a patient with advanced pulmonary adenocarcinoma.

International cancer conference journal 2021 Jan;10;68-71 — 2021 Jan — 68-71

Watanabe H, Ichihara E, Kano H, Ninomiya K, Tanimoto M, Kiura K

Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC).

Internal medicine (Tokyo, Japan) 2017 Aug 15;56;2195-2197 — 2017 Aug 15 — 2195-2197